Revenue: As of FY2025 Q2, the actual value is USD 9.813 M.EPS: As of FY2025 Q2, the actual value is USD 0.EBIT: As of FY2025 Q2, the actual value is USD 15 K.<h3>Segment Revenue</h3><ul><li>Primary Reporting Unit: Net sales of $9,493,000 for the three months ended June 30, 2025, and $19,899,000 for the six months ended June 30, 2025.</li><li>China: Net sales of $219,000 for the three months ended June 30, 2025, and $453,000 for the six months ended June 30, 2025.</li><li>Russia and Kazakhstan: Net sales of $101,000 for the three months ended June 30, 2025, and $198,000 for the six months ended June 30, 2025.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: $7,255,000 for the three months ended June 30, 2025, compared to $7,776,000 for the same period in 2024. Gross profit was $15,160,000 for the six months ended June 30, 2025, compared to $15,815,000 for the same period in 2024.</li><li>Operating Expenses: Total operating expenses were $7,588,000 for the three months ended June 30, 2025, compared to $8,014,000 for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $15,838,000 compared to $16,418,000 in 2024.</li><li>Net Income: $15,000 for the three months ended June 30, 2025, compared to $173,000 for the same period in 2024. Net income was $137,000 for the six months ended June 30, 2025, compared to $361,000 in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities was -$5,151,000 for the six months ended June 30, 2025, compared to -$3,019,000 for the same period in 2024.</li><li>Investing Cash Flow: Net cash provided by investing activities was $6,643,000 for the six months ended June 30, 2025, compared to -$32,887,000 for the same period in 2024.</li><li>Financing Cash Flow: Net cash used in financing activities was -$4,606,000 for the six months ended June 30, 2025, consistent with the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to focus resources on Greater China and countries where existing members have connections to recruit prospects and sell products, such as Southeast Asia, India, South America, and Europe. The company is also investing in its Mainland China entity to establish China-based manufacturing capabilities and increase public awareness of its brand and products.</li><li>Non-Core Business: The company is evaluating options to transition production of certain products currently manufactured in the United States to other jurisdictions, including in Asia, to mitigate the effect of U.S. and reciprocal tariffs.</li></ul>

Natural Health Trend | 10-Q: FY2025 Q2 Revenue: USD 9.813 M